VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

SG33-VP2/5
Vaccine Information
  • Vaccine Name: SG33-VP2/5
  • Target Pathogen: Bluetongue virus
  • Target Disease: Bluetongue disesase
  • Vaccine Ontology ID: VO_0004706
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Sheep
  • Vector: myxoma virus vaccine vector
  • Preparation: MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012)
  • Immunization Route: Other
Host Response

Sheep Response

  • Vaccination Protocol: Sheep were injected twice with an MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012).
  • Vaccine Immune Response Type: VO_0000287
  • Immune Response: The SG33-VP2 vector promoted the production of neutralising antibodies (Maclachlan et al., 2009).
  • Efficacy: The SG33-VP2 vector expressing VP2 partially protected sheep against disease after challenge with a highly virulent strain of serotype-8 bluetongue virus (BTV-8) (Top et al., 2012).
References
Maclachlan et al., 2009: Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. Journal of comparative pathology. 2009; 141(1); 1-16. [PubMed: 19476953].
Top et al., 2012: Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli S, Meyer G. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Vaccine. 2012; 30(9); 1609-1616. [PubMed: 22244980].